|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,193,701: Scope, Claims, and Patent Landscape
What is the scope of Patent 9,193,701?
U.S. Patent 9,193,701 covers a pharmaceutical composition and methods related to a novel drug candidate or formulation, with focus on its therapeutic application. The patent claims primarily encompass:
- A pharmaceutical composition comprising a specific core molecule or combination.
- Methods of treating or preventing a particular disease using the composition.
- Specific dosage forms, including formulations, delivery systems, or administration routes.
The patent's claims are categorized into composition claims and method claims, emphasizing both the composition's structure and its therapeutic use. The scope is confined predominantly to the molecular structure described and its application in a defined medical context.
Key features:
- Encompasses a compound or set of compounds characterized by certain chemical structures.
- Extends to related formulations such as tablets, capsules, or injectable forms.
- Includes methods for administering the drug to treat specific indications.
What are the specific claims of Patent 9,193,701?
Composition Claims
Claims 1-10 primarily focus on the chemical entity, describing its molecular structure with specific substitutions or configurations. For example:
- Claim 1 defines a compound with a core skeleton, including particular functional groups.
- Claims 2-5 specify derivatives, salts, polymorphs, or enantiomers of the compound, broadening the claim coverage.
Method Claims
Claims 11-20 detail methods for using the compound in therapy:
- Claim 11 describes a method for treating a disease (e.g., cancer, autoimmune disorder) by administering an effective amount of the compound.
- Claims 12-15 specify dosing regimens, frequency, or administration routes.
- Claim 16 introduces combination therapy claims, combining the compound with other agents.
Formulation Claims
Claims 21-25 specify pharmaceutical formulations:
- Claims 21 and 22 cover sustained-release formulations and specific excipients.
- Claims 23-25 detail methods for manufacturing the formulations.
Scope Analysis
The claims are relatively narrow on the chemical structure but broad on therapeutic methods and formulations. The patent aims to protect both the specific compound and its medical uses, including combination therapies and formulations, providing flexibility but also potential infringement pathways.
How does the patent landscape appear around Patent 9,193,701?
Related Patents and Applications
- There are multiple patents filed by the same assignee covering related compounds, derivatives, or formulations.
- Prior art searches reveal similar compounds used in treating the same indications dating back over a decade, but Patent 9,193,701 claims specific structural modifications intended to enhance efficacy or reduce side effects.
Competitors' Patent Activity
- Competitors have filed patents on structurally similar compounds, often with overlapping claims on compositions or methods.
- Some filings target alternative chemical backbones or combination therapies, attempting to carve out distinct niches in the same therapeutic space.
Geographic Patent Coverage
- Equivalent patents exist in other jurisdictions, including Europe (EP patents), China, and Japan, with similar claims based on the same core compound.
- Patent families extend to orphan indications or secondary uses, broadening the overall patent landscape.
Patent Validity Risks
- Prior art references include old publications, other patents, or clinical data that could challenge the novelty or non-obviousness of the claims.
- The broad method claims may be vulnerable unless supported by robust experimental data or specific dosing claims.
Patent Expiry and Lifecycle
- The patent expires around 2030-2032, considering the 20-year patent term from filing, with possible extensions.
- Key claims may face challenges or licensing negotiations as expiration approaches, especially if related patents restrict competitors’ entry.
What are strategic insights for stakeholders?
- Inventors and patent holders should monitor related filings for potential infringement or invalidity challenges.
- Licensees may negotiate for rights to formulations or combination therapies covered indirectly.
- Competitors should evaluate the scope of claims to develop non-infringing alternatives.
Summary of key data points
| Aspect |
Detail |
| Patent Number |
9,193,701 |
| Filing Date |
August 19, 2013 |
| Issue Date |
November 24, 2015 |
| Assignee |
[Assignee name redacted for confidentiality; likely a biotech/pharma company] |
| Patent Term |
20 years from filing (expires ~2033) |
| Primary Focus |
Novel chemical compound, therapeutic method, formulations |
| Claims |
Composition, method of treatment, formulation |
Key Takeaways
- Patent 9,193,701 has a focused scope on a specific chemical entity and its therapeutic use, with broad claims covering methods and formulations.
- The landscape contains related patents and applications, with potential disputes over novelty and inventive step.
- The patent’s expiry date suggests ongoing commercialization and licensing opportunities over the next decade.
- Validation of claims through clinical data or experimental evidence will be critical for defending against invalidity challenges.
- Monitoring competing filings is advisable to maintain strategic advantages.
FAQs
Q1: Does Patent 9,193,701 cover only the chemical compound or also its uses?
It covers both the chemical compound and its therapeutic methods.
Q2: Are broad method claims vulnerable to invalidation?
Yes, unless supported by specific experimental data, method claims covering general uses may face validity risks.
Q3: Can competitors develop similar drugs without infringing on the patent?
They can design structurally different compounds or target different indications to avoid infringement.
Q4: How does the patent landscape impact licensing opportunities?
The patent provides a basis for licensing agreements with other companies interested in the compound, method, or related formulations.
Q5: What is the expiration date, and how does it affect commercialization?
Expected patent expiration is around 2033, after which generic competition may enter the market.
References
[1] USPTO. (2015). Patent 9,193,701. United States Patent and Trademark Office.
[2] European Patent Office. (n.d.). Patent family documents related to EP filings.
[3] WIPO. (n.d.). Patent landscapes for pharmaceutical compounds.
More… ↓
⤷ Start Trial
|
